BRPI0511623A - heterociclos bicìclicos como inibidores de hiv integrase - Google Patents

heterociclos bicìclicos como inibidores de hiv integrase

Info

Publication number
BRPI0511623A
BRPI0511623A BRPI0511623-6A BRPI0511623A BRPI0511623A BR PI0511623 A BRPI0511623 A BR PI0511623A BR PI0511623 A BRPI0511623 A BR PI0511623A BR PI0511623 A BRPI0511623 A BR PI0511623A
Authority
BR
Brazil
Prior art keywords
hiv integrase
hiv
bicyclic heterocycles
integrase inhibitors
bicyclic
Prior art date
Application number
BRPI0511623-6A
Other languages
English (en)
Portuguese (pt)
Inventor
B Narasimhulu Naidu
Jacques Banville
Francis Beaulieu
Timothy P Connoly
Mark R Krystal
John D Matiskella
Carl Ouellet
Serge Plamondon
Roger Remillard
Margaret E Sorenson
Yasutsugu Ueda
Michael A Walker
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0511623A publication Critical patent/BRPI0511623A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0511623-6A 2004-05-28 2005-05-12 heterociclos bicìclicos como inibidores de hiv integrase BRPI0511623A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57551304P 2004-05-28 2004-05-28
US60337104P 2004-08-20 2004-08-20
US11/126,891 US7176196B2 (en) 2004-05-28 2005-05-11 Bicyclic heterocycles as HIV integrase inhibitors
PCT/US2005/016473 WO2005118593A1 (en) 2004-05-28 2005-05-12 Bicyclic heterocycles as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0511623A true BRPI0511623A (pt) 2008-03-11

Family

ID=35456854

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511623-6A BRPI0511623A (pt) 2004-05-28 2005-05-12 heterociclos bicìclicos como inibidores de hiv integrase

Country Status (26)

Country Link
US (2) US7176196B2 (enExample)
EP (1) EP1749011B1 (enExample)
JP (1) JP4874959B2 (enExample)
KR (1) KR101097623B1 (enExample)
AR (1) AR049124A1 (enExample)
AT (1) ATE412656T1 (enExample)
AU (1) AU2005250356C1 (enExample)
BR (1) BRPI0511623A (enExample)
CA (1) CA2568356C (enExample)
CY (1) CY1110266T1 (enExample)
DE (1) DE602005010690D1 (enExample)
DK (1) DK1749011T3 (enExample)
ES (1) ES2315875T3 (enExample)
HR (1) HRP20090005T3 (enExample)
IL (1) IL179455A (enExample)
MX (1) MXPA06013835A (enExample)
NO (1) NO20065879L (enExample)
NZ (1) NZ551282A (enExample)
PE (1) PE20060242A1 (enExample)
PL (1) PL1749011T3 (enExample)
PT (1) PT1749011E (enExample)
RS (1) RS50700B (enExample)
RU (1) RU2381228C2 (enExample)
SI (1) SI1749011T1 (enExample)
TW (1) TWI366567B (enExample)
WO (1) WO2005118593A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
EP1866313A1 (en) * 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
JP5094725B2 (ja) 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Hivインテグラーゼ阻害剤
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (en) * 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
WO2007064502A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7897593B2 (en) * 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2007275805A1 (en) * 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009120841A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate
EP2349276B1 (en) * 2008-10-06 2019-11-27 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
US8383639B2 (en) * 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
KR20120094098A (ko) 2009-12-07 2012-08-23 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 피리디논 하이드록시사이클로펜틸 카복사미드: 치료 용도의 hiv 인테그라제 억제제
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2807149A2 (en) * 2012-01-26 2014-12-03 CRO Consulting Limited Agents for treating neurodegenerative disorders
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
ES2656696T3 (es) 2013-05-17 2018-02-28 Merck Sharp & Dohme Corp. Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del VIH
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en) 2016-12-02 2020-11-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
WO2021050555A1 (en) * 2019-09-10 2021-03-18 X-Chem, Inc. Compositions and uses thereof
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693641A (en) * 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
EP1441735B1 (en) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7094783B2 (en) * 2002-06-26 2006-08-22 Bristol-Myers Squibb Company Bicyclic pyrimidinones as coagulation cascade inhibitors
AU2003292436B2 (en) 2002-12-27 2009-07-30 Msd Italia S.R.L. Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
MX2007006637A (es) 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
EP1866313A1 (en) 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors

Also Published As

Publication number Publication date
MXPA06013835A (es) 2007-02-02
IL179455A0 (en) 2007-05-15
SI1749011T1 (sl) 2009-08-31
PE20060242A1 (es) 2006-03-31
RU2006146970A (ru) 2008-07-10
WO2005118593A1 (en) 2005-12-15
US20050267105A1 (en) 2005-12-01
TW200600503A (en) 2006-01-01
RS50700B (sr) 2010-06-30
JP2008501018A (ja) 2008-01-17
RU2381228C2 (ru) 2010-02-10
TWI366567B (en) 2012-06-21
AR049124A1 (es) 2006-06-28
AU2005250356A1 (en) 2005-12-15
KR20070039502A (ko) 2007-04-12
PT1749011E (pt) 2008-11-27
NZ551282A (en) 2009-05-31
CA2568356A1 (en) 2005-12-15
KR101097623B1 (ko) 2011-12-22
CA2568356C (en) 2012-07-03
DK1749011T3 (da) 2009-02-16
AU2005250356C1 (en) 2011-10-06
CY1110266T1 (el) 2015-01-14
US20060276466A1 (en) 2006-12-07
EP1749011B1 (en) 2008-10-29
PL1749011T3 (pl) 2009-04-30
ES2315875T3 (es) 2009-04-01
NO20065879L (no) 2007-02-20
HK1107343A1 (en) 2008-04-03
JP4874959B2 (ja) 2012-02-15
ATE412656T1 (de) 2008-11-15
EP1749011A1 (en) 2007-02-07
DE602005010690D1 (de) 2008-12-11
US7511037B2 (en) 2009-03-31
IL179455A (en) 2011-10-31
US7176196B2 (en) 2007-02-13
HRP20090005T3 (hr) 2009-02-28
AU2005250356B2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
BRPI0511623A (pt) heterociclos bicìclicos como inibidores de hiv integrase
TW200738728A (en) HIV integrase inhibitors
NO20082135L (no) HIV integrase inhibitorer
BRPI0511078A (pt) compostos de pirimidinona cìclicos, composição compreendendo os mesmos, método de inibição e uso
WO2008002959A3 (en) Hiv integrase inhibitors
CY1126771T1 (el) Συνδυασμοι δολουτεγραβιρης και λαμιβουδινης για την αγωγη λοιμωξης απο hiv
NO20080797L (no) Bicykliske heterocykler som HIV Integrase inhibitorer
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
MX383447B (es) Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
EP2320909A4 (en) CHEMICAL COMPOUNDS
BR112013011737A2 (pt) composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
HN2005000449A (es) Inhibidores de arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamiento que lo usan
WO2007059125A3 (en) Hiv integrase inhibitors
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
EA200901080A1 (ru) Новые нуклеозидные аналоги для лечения вирусных инфекций
BR112015012842A2 (pt) diazol lactamas
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
ATE539155T1 (de) Targets und zusammensetzungen zur therapeutischen intervention bei hiv-infektion
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]